Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DTIL NASDAQ:EQ NASDAQ:RNAC NASDAQ:TLPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDTILPrecision BioSciences$6.10-1.1%$7.05$3.53▼$8.82$157.39M1.3365,023 shs236,014 shsEQEquillium$2.81$2.28$0.27▼$3.45$177.67M1.771.14 million shs441,284 shsRNACCartesian Therapeutics$9.51+18.0%$6.95$5.60▼$15.57$279.42M0.66366,818 shs877,601 shsTLPHTalphera$0.87+5.2%$0.81$0.38▼$1.57$45.33M0.76138,624 shs233,766 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDTILPrecision BioSciences-1.13%-6.15%-26.86%+7.58%+20.32%EQEquillium-0.74%-4.42%+21.65%+13.77%+627.98%RNACCartesian Therapeutics+17.99%+62.84%+12.95%+28.69%-8.65%TLPHTalphera+5.23%+12.70%-3.10%+9.61%+70.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDTILPrecision BioSciences$6.10-1.1%$7.05$3.53▼$8.82$157.39M1.3365,023 shs236,014 shsEQEquillium$2.81$2.28$0.27▼$3.45$177.67M1.771.14 million shs441,284 shsRNACCartesian Therapeutics$9.51+18.0%$6.95$5.60▼$15.57$279.42M0.66366,818 shs877,601 shsTLPHTalphera$0.87+5.2%$0.81$0.38▼$1.57$45.33M0.76138,624 shs233,766 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDTILPrecision BioSciences-1.13%-6.15%-26.86%+7.58%+20.32%EQEquillium-0.74%-4.42%+21.65%+13.77%+627.98%RNACCartesian Therapeutics+17.99%+62.84%+12.95%+28.69%-8.65%TLPHTalphera+5.23%+12.70%-3.10%+9.61%+70.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDTILPrecision BioSciences 2.60Moderate Buy$32.25428.69% UpsideEQEquillium 2.78Moderate Buy$7.57169.45% UpsideRNACCartesian Therapeutics 2.67Moderate Buy$32.60242.80% UpsideTLPHTalphera 2.25Hold$3.00243.49% UpsideCurrent Analyst Ratings BreakdownLatest TLPH, EQ, DTIL, and RNAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026RNACCartesian Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$38.006/9/2026DTILPrecision BioSciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$20.006/9/2026RNACCartesian Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.006/9/2026RNACCartesian Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$44.006/8/2026TLPHTalphera Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/5/2026TLPHTalphera HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$3.005/28/2026EQEquillium Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$7.005/28/2026EQEquillium Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.005/28/2026EQEquillium Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/28/2026EQEquillium Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$1.00 ➝ $6.005/27/2026DTILPrecision BioSciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.00(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDTILPrecision BioSciences$34.26M4.59N/AN/A$4.03 per share1.51EQEquillium$41.10M4.32N/AN/A$0.47 per share5.98RNACCartesian Therapeutics$2.80M99.79N/AN/A($4.85) per share-1.96TLPHTalphera$30K1,510.98N/AN/A$0.37 per share2.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDTILPrecision BioSciences-$45.72M-$3.67N/AN/AN/A-96.73%-85.37%-37.34%8/6/2026 (Estimated)EQEquillium-$22.40M-$0.32N/AN/AN/AN/A-61.43%-53.72%8/13/2026 (Estimated)RNACCartesian Therapeutics-$130.30M-$5.90N/AN/AN/A-8,550.65%N/A-28.25%8/6/2026 (Estimated)TLPHTalphera-$14.29M-$0.31N/AN/AN/AN/A-92.98%-53.22%8/13/2026 (Estimated)Latest TLPH, EQ, DTIL, and RNAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026EQEquillium-$0.04-$0.06-$0.02-$0.06N/AN/A5/13/2026Q1 2026TLPHTalphera-$0.07-$0.04+$0.03-$0.04N/AN/A5/5/2026Q1 2026DTILPrecision BioSciences-$0.6550-$0.75-$0.0950-$0.75$4.05 million$10.84 million4/30/2026Q1 2026RNACCartesian Therapeutics-$0.84-$1.46-$0.62-$1.46$0.22 million$0.08 million3/25/2026Q4 2025EQEquillium-$0.07-$0.04+$0.03-$0.04N/AN/A3/23/2026Q4 2025 & Investor DayTLPHTalphera-$0.0750-$0.06+$0.0150-$0.06$0.58 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDTILPrecision BioSciencesN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/ATLPHTalpheraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDTILPrecision BioSciences0.2914.0214.02EQEquilliumN/A18.6218.62RNACCartesian TherapeuticsN/A7.657.65TLPHTalpheraN/A5.305.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDTILPrecision BioSciences37.99%EQEquillium27.05%RNACCartesian Therapeutics86.95%TLPHTalphera37.67%Insider OwnershipCompanyInsider OwnershipDTILPrecision BioSciences2.70%EQEquillium17.84%RNACCartesian Therapeutics37.20%TLPHTalphera3.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDTILPrecision BioSciences20025.80 million25.11 millionNo DataEQEquillium4063.23 million51.95 millionNot OptionableRNACCartesian Therapeutics6429.38 million18.45 millionOptionableTLPHTalphera1951.90 million50.08 millionOptionableTLPH, EQ, DTIL, and RNAC HeadlinesRecent News About These CompaniesResearch Analysts Offer Predictions for Talphera Q2 EarningsJune 8, 2026 | americanbankingnews.comTalphera (NASDAQ:TLPH) Shares Up 4.5% - Should You Buy?June 5, 2026 | americanbankingnews.comTalphera (TLPH) CEO Angotti buys $85k in sharesMay 21, 2026 | investing.comTalphera Earnings Call Highlights NEPHRO Trial MomentumMay 19, 2026 | tipranks.comTalphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ...May 15, 2026 | finance.yahoo.comTalphera Earnings Call Highlights Trial Momentum, RisksMay 14, 2026 | tipranks.comTalphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate UpdateMay 14, 2026 | finanznachrichten.deTalphera, Inc. (TLPH) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comTalphera Q1 2026 Earnings Call TranscriptMay 13, 2026 | finance.yahoo.comTalphera targets Niyad PMA filing in 2026 and potential approval in 2027 as NEPHRO enrollment surpasses 50%May 13, 2026 | seekingalpha.comTalphera (TLPH) Q1 2026 Earnings TranscriptMay 13, 2026 | fool.comTalphera Announces First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | prnewswire.comTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026May 7, 2026 | prnewswire.comWestPark Capital initiates coverage of Talphera (TLPH) with buy recommendationMay 1, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC), Talphera (TLPH) and Abivax SA Sponsored ADR (ABVX)March 26, 2026 | theglobeandmail.comTalphera (NASDAQ:TLPH) CEO Acquires $125,852.90 in StockMarch 26, 2026 | insidertrades.comTalphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026March 25, 2026 | prnewswire.comTalphera, Inc.: Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 24, 2026 | finanznachrichten.deTalphera, Inc. (TLPH) Analyst/Investor Day TranscriptMarch 24, 2026 | seekingalpha.comTalphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 23, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesFrom High-Yield to High-Growth: 3 Stocks Boosting DividendsBy Leo Miller | May 18, 2026Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIABy Jeffrey Neal Johnson | May 21, 2026The SpaceX IPO Frenzy Is Creating 2 Very Different BetsBy Jeffrey Neal Johnson | May 27, 2026A Deep Dive Into NVIDIA’s Latest Portfolio MovesBy Leo Miller | May 19, 2026Tesla Ends Model S and X Era, Bets Everything on What's NextBy Sam Quirke | May 20, 2026TLPH, EQ, DTIL, and RNAC Company DescriptionsPrecision BioSciences NASDAQ:DTIL$6.10 -0.07 (-1.13%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$6.10 0.00 (0.00%) As of 06/12/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Equillium NASDAQ:EQ$2.81 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$2.72 -0.09 (-3.02%) As of 06/12/2026 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Cartesian Therapeutics NASDAQ:RNAC$9.51 +1.45 (+17.99%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$9.58 +0.07 (+0.74%) As of 06/12/2026 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.Talphera NASDAQ:TLPH$0.87 +0.04 (+5.23%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$0.87 0.00 (-0.05%) As of 06/12/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
